Growth Metrics

Codexis (CDXS) Revenue (2010 - 2026)

Codexis' quarterly Revenue came in at $15.2 million in Q1 2026, up 102.15% year-on-year from $7.5 million in Q1 2025, and down 60.82% quarter-over-quarter from $38.9 million in Q4 2025.

Codexis has reported Revenue for 17 years, with the latest figure at $15.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Revenue rose 102.15% year-over-year to $15.2 million; the trailing twelve-month figure through Mar 2026 stood at $78.1 million (up 56.76% YoY), and the FY2025 full-year result was $70.4 million, up 18.61% from the prior year.
  • Revenue for Q1 2026 stood at $15.2 million, down from $38.9 million in the prior quarter.
  • The five-year high for Revenue was $38.9 million in Q4 2025, with the low at $5.0 million in Q2 2023.
  • Average Revenue over 5 years is $18.0 million, with a median of $15.2 million recorded in 2026.
  • Year-over-year, Revenue sank 86.98% in 2023 and soared 329.2% in 2024.
  • Tracing CDXS's Revenue over 5 years: stood at $19.8 million in 2022, then plunged by 74.75% to $5.0 million in 2023, then soared by 329.2% to $21.5 million in 2024, then soared by 81.34% to $38.9 million in 2025, then plunged by 60.82% to $15.2 million in 2026.
  • The last three Revenue figures came in at $15.2 million (Q1 2026), $38.9 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.17 Bn
10 Codexis 251.43 Mn 186.29 Mn 13.18 Mn 15.25 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 15.25 Mn
Dec 31, 2025 38.92 Mn
Sep 30, 2025 8.60 Mn
Jun 30, 2025 15.33 Mn
Mar 31, 2025 7.54 Mn
Dec 31, 2024 21.46 Mn
Sep 30, 2024 12.83 Mn
Jun 30, 2024 7.98 Mn
Mar 31, 2024 17.07 Mn
Dec 31, 2023 5.00 Mn
Sep 30, 2023 9.28 Mn
Jun 30, 2023 5.00 Mn
Mar 31, 2023 12.98 Mn
Dec 31, 2022 19.80 Mn
Sep 30, 2022 34.47 Mn
Jun 30, 2022 38.41 Mn
Mar 31, 2022 35.34 Mn
Dec 31, 2021 24.50 Mn
Sep 30, 2021 36.77 Mn
Jun 30, 2021 25.45 Mn
Mar 31, 2021 18.03 Mn
Dec 31, 2020 21.03 Mn
Sep 30, 2020 18.39 Mn
Jun 30, 2020 14.97 Mn
Mar 31, 2020 14.67 Mn
Dec 31, 2019 18.65 Mn
Sep 30, 2019 21.91 Mn
Jun 30, 2019 12.32 Mn
Mar 31, 2019 15.58 Mn
Dec 31, 2018 16.07 Mn
Sep 30, 2018 16.95 Mn
Jun 30, 2018 13.54 Mn
Mar 31, 2018 14.04 Mn
Dec 31, 2017 21.72 Mn
Sep 30, 2017 9.98 Mn
Jun 30, 2017 300,000.00
Mar 31, 2017 5.59 Mn
Dec 31, 2016 9.97 Mn
Sep 30, 2016 14.87 Mn
Jun 30, 2016 16.00 Mn
Mar 31, 2016 8.00 Mn
Dec 31, 2015 11.59 Mn
Sep 30, 2015 1.82 Mn
Jun 30, 2015 2.02 Mn
Mar 31, 2015 3.08 Mn
Dec 31, 2014 4.74 Mn
Sep 30, 2014 7.47 Mn
Jun 30, 2014 2.78 Mn
Mar 31, 2014 7.07 Mn
Dec 31, 2013 5.26 Mn
Sep 30, 2013 3.94 Mn
Jun 30, 2013 4.95 Mn
Mar 31, 2013 9.14 Mn
Dec 31, 2012 7.91 Mn
Sep 30, 2012 7.14 Mn
Jun 30, 2012 258,000.00
Mar 31, 2012 31.14 Mn
Dec 31, 2011 33.49 Mn
Sep 30, 2011 12.20 Mn
Jun 30, 2011 273,000.00
Mar 31, 2011 31.03 Mn
Dec 31, 2010 29.81 Mn
Sep 30, 2010 27.11 Mn
Jun 30, 2010 8.48 Mn